JP2007008965A - Hair growing agent - Google Patents
Hair growing agent Download PDFInfo
- Publication number
- JP2007008965A JP2007008965A JP2006287967A JP2006287967A JP2007008965A JP 2007008965 A JP2007008965 A JP 2007008965A JP 2006287967 A JP2006287967 A JP 2006287967A JP 2006287967 A JP2006287967 A JP 2006287967A JP 2007008965 A JP2007008965 A JP 2007008965A
- Authority
- JP
- Japan
- Prior art keywords
- herbal medicine
- hair restorer
- administered
- administration
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
Description
本発明は、育毛剤に関する。 The present invention relates to a hair restorer.
漢方の思想には、気、血、水の概念があり、これらのバランスを保つことにより正常な生命生活が営まれるとされている。このうち水の概念は、汗や尿などの水分を介する代謝系を表すものであり、津液はこの代謝系を活性化する概念である。この様な津液の働きを改善する生薬としては、攻下薬、潤下薬、峻下薬、利水薬、消導薬、解表薬、去風湿薬、活血薬、補陽薬、補陰薬、芳香開窮薬、化痰止咳薬、芳香開窮薬等に分類されるものが相当し、具体的には、次に示すものが挙げられる。これらの生薬を摂取することにより、水分代謝を高め、汗、尿、各種消化液の分泌が盛んになり、人体の不要物が対外に運び出される作用が高まることは既に知られている。しかしながら、これら津液改善剤と各種の薬効を有する物質との相互作用については何も知られていないのが現状である。
（津液作用を改善する生薬）ダイオウ、センナ、アロエ、イクリニン、ケンゴシ、カンスイ、ゲンカ、タイゲキ、ショウリク、ゾクズイシ、テイレキシ、ウキュウコンピ、ブクリョウ、チョレイ、インチンコウ、モクボウイ、カンボウイ、ヨクイニン、トウカニン、ツウヤク、クバク、ジフシ、ヘンチク、セキイ、シャゼンシ、トウキシ、ヒカイ、キンセンソウ、セキショウズ、ハンペンレイ、ギョクマイシュ、サンザシ、バクガ、ケイナイキン、ライフクシ、マオウ、シソヨウ、ケイガイ、ボウフウ、コウジュ、ゴボウシ、フヘイ、モクゾク、セキナントウ、ウコン、コトウニク、シャジン、テンモンドウ、バクモンドウ、ギョクチク、ヒャクゴウ、ソウキセイ、ショウブ、バクガイシ、ゴオウ
Kampo's philosophy includes the concept of qi, blood, and water, and it is said that a normal life can be maintained by maintaining a balance between these. Of these, the concept of water represents a metabolic system through water such as sweat and urine, and tsuyu is a concept that activates this metabolic system. Herbal medicines that improve the workings of such liquids are ascending drugs, laxatives, steep laxatives, diuretics, decongestants, anti-tabular medicines, gout moisturizers, active blood drugs, prosthetics, and prosthetics Those classified into medicines, fragrance-opening agents, anti-fogging cough agents, fragrance-opening agents and the like correspond to the following, and specific examples include the following. It is already known that taking these herbal medicines increases water metabolism, increases the secretion of sweat, urine, and various digestive juices, and enhances the action of carrying unnecessary substances from the human body to the outside. However, at present, nothing is known about the interaction between these liquid ameliorating agents and substances having various medicinal effects.
(Drugs, senna, aloe, icrinin, kengoshi, kansui, genka, tiger geese, shrimp, zokuzui, taleki, kyukoukonpi, bukuryo, chorei, ginseng, mokuboui, kanboui, yokuinin, toukaku, takuyaku Gyfushi, henchik, sekii, shazenshi, toki, hikai, kinsou, sekishozu, hanpen rei, gyokumaiish, hawthorn, bakuga, keinaikin, life sushi, maou, shisoyou, kei-gai, boufuu, koju, burdock, fuhei, mokzok, seikonoku, seikonoku, Shajin, Tenmondou, Bakumondou, Kyokuchiku, Hyakugou, Sakusei, Shobu, Bakugaishi, Gooh
一方、各種薬理作用を有する物質を治療などに用いる場合特に留意されるべきことは、これら薬理作用を有する物質の体内に於ける分布や生体利用度がどの様であるかを知ることである。これは、多くの薬物に於いて生体内分布や生体利用度は決して良いとは言えない場合が多く、期待した効果がその薬物投与から得られない場合が少ないからである。即ち、これら薬理作用を有する物質の体内分布や生体利用度を改善することにより、薬理作用を向上することができるため、この様な方法の登場が待ち望まれていた。 On the other hand, when a substance having various pharmacological actions is used for treatment or the like, it is particularly important to know how the substances having these pharmacological actions are distributed in the body and the bioavailability. This is because in many drugs, the biodistribution and bioavailability are often not good, and the expected effect is not often obtained from the drug administration. That is, since the pharmacological action can be improved by improving the in vivo distribution and bioavailability of these substances having a pharmacological action, the advent of such a method has been awaited.
更に、特定の成分を経口投与することにより、経皮投与された薬理作用を有する物質の経皮吸収や体内への分布が改善される様な話は全く知られていない。 Furthermore, there is no known story that oral administration of a specific component improves the transdermal absorption and distribution in the body of a substance having a pharmacological action administered transdermally.
本発明は、かかる状況を踏まえて為されたものであり、薬理作用を有する物質の体内分布や生体利用度を改善する手段を提供することを課題とする。 The present invention has been made in view of such circumstances, and an object of the present invention is to provide means for improving the biodistribution and bioavailability of a substance having a pharmacological action.
本発明者らは、かかる状況に鑑みて、薬理作用を有する物質の体内分布や生体利用度を改善する手段を求め、鋭意研究を重ねた結果、津液作用を有する生薬のエッセンスにその様な作用を見いだし、発明を完成させるに至った。以下、本発明について発明の実施の形態を中心に詳細に説明を加える。 In view of such circumstances, the present inventors have sought a means for improving the biodistribution and bioavailability of substances having pharmacological effects, and as a result of earnest research, as a result of such actions on the essence of herbal medicines having a tsunami action. And found the invention. Hereinafter, the present invention will be described in detail focusing on the embodiment of the invention.
（１）本発明で使用する津液作用を有する生薬本発明で使用される生薬は、漢方の分類に於いて、攻下薬、潤下薬、峻下薬、利水薬、消導薬、解表薬、去風湿薬、活血薬、補陽薬、補陰薬、芳香開窮薬、化痰止咳薬、芳香開窮薬に分類されるものであり、これらのものは津液作用を改善することが知られている。具体的な生薬としては、ダイオウ、センナ、
アロエ、イクリニン、ケンゴシ、カンスイ、ゲンカ、タイゲキ、ショウリク、ゾクズイシ、テイレキシ、ウキュウコンピ、ブクリョウ、チョレイ、インチンコウ、モクボウイ、カンボウイ、ヨクイニン、トウカニン、ツウヤク、クバク、ジフシ、ヘンチク、セキイ、シャゼンシ、トウキシ、ヒカイ、キンセンソウ、セキショウズ、ハンペンレイ、ギョクマイシュ、サンザシ、バクガ、ケイナイキン、ライフクシ、マオウ、シソヨウ、ケイガイ、ボウフウ、コウジュ、ゴボウシ、フヘイ、モクゾク、セキナントウ、ウコン、コトウニク、シャジン、テンモンドウ、バクモンドウ、ギョクチク、ヒャクゴウ、ソウキセイ、ショウブ、バクガイシ、ゴオウ等が挙げられる。本発明では、これら生薬を原体のまま使用することも可能であるし、抽出物やその溶媒除去物、更にはその分画精製物として使用することも可能である。本発明に於けるエッセンスとはこれらの総称を意味する。特に好ましいものは溶媒抽出物乃至はその溶媒除去物である。抽出物は、生薬又はその粉砕などした加工物に１〜１０倍量の溶媒を加え、沸点付近の温度であれば数時間、室温であれば数日間浸漬することによって得ることができる。使用する溶媒としては、極性溶媒が好ましく、例えば、水、エタノールやプロピレングリコール等のアルコール類、酢酸エチルや蟻酸メチルなどのエステル類、ジエチルエーテルやテトラヒドロフラン等のエーテル類、アセトンやメチルエチルケトン等のケトン類、塩化メチレンやクロロホルム等のハロゲン化炭化水素から選ばれる１種乃至は２種以上が好ましく例示できる。特に好ましいのは水抽出物乃至はその溶媒除去物である。本発明に於いては、これらの生薬類は経口投与される。この投与により、経口とは異なった経路で投与された薬理活性物質の生体内への吸収、疾患部位への到達が改善され、当該薬理活性物質の生体利用率を高めることができる。本発明のこれら薬理活性物質の分布改善剤である津液作用を有する生薬のエッセンスの好ましい投与量は、成人一人一日当たり、１０〜２００００ｇを一回乃至は数回に分けて投与するのが好適である。投与は、薬理活性物質の投与に先立って行われるのが好ましく、タイミングとしては、薬理活性物質投与の１時間〜３０分前に行うのが好ましい。又、特に注目すべきは、血液の影響の少ない皮膚からの薬理活性物質の吸収と疾患部位への到達を改善することである。即ち、これは血液による新陳代謝、吸収、排泄に大きな期待ができない皮膚に於いては、漢方に言う津液作用がこの作用を代って担っているためである。尚、本発明の薬理活性物質の分布改善剤は、賦形剤、結合剤、被覆剤、滑沢剤、糖衣剤、崩壊剤、増量剤、矯味矯臭剤、乳化・可溶化・分散剤、安定剤、ｐＨ調整剤、等張剤等の任意成分と共に製剤化して使用することも可能である。
(1) Herbal medicines having squeezing action used in the present invention The herbal medicines used in the present invention are, according to Kampo classification, a laxative drug, a laxative drug, a steep drug, a water-use drug, a decontamination drug, an answer table Drugs, gouty moisturizers, active agents, prosthetics, antidepressants, fragrance-opening agents, antifocal cough agents, and fragrance-opening agents. It has been known. Specific herbal medicines include Daio, Senna,
Aloe, Icrinin, Kengoshi, Kansui, Genka, Taikiki, Shorikiku, Zokuzuishi, Teirexi, Ukyukoupi, Bukuryo, Chorei, Inchinkou, Mokuboui, Kamboui, Yokuinin, Tokanin, Tsuyaku, Kakukaku, Difushi, Henchiku, Shichiki, Shiki Shiki Ginseng, Sekisho, Hanpen Rei, Gokumaishu, Hawthorn, Bakuga, Keinai Kin, Life Kushi, Maou, Shisoyo, Keigai, Bowfu, Kouju, Goboushi, Fuhei, Mokuzoku, Sekinanto, Turmeric, Kotonik, Shajin, Ginseng, Ginkgo Examples include shobu, scallops and gourd. In the present invention, these crude drugs can be used as they are, or can be used as an extract, a solvent-removed product thereof, or a fraction-purified product thereof. The essence in the present invention means a generic name of these. Particularly preferred are solvent extracts or solvent removal products thereof. An extract can be obtained by adding 1 to 10 times the amount of a solvent to a crude drug or a processed product thereof, and immersing it for several hours at a temperature near the boiling point or for several days at room temperature. The solvent used is preferably a polar solvent, for example, water, alcohols such as ethanol and propylene glycol, esters such as ethyl acetate and methyl formate, ethers such as diethyl ether and tetrahydrofuran, and ketones such as acetone and methyl ethyl ketone. One or two or more selected from halogenated hydrocarbons such as methylene chloride and chloroform can be preferably exemplified. Particularly preferred is a water extract or a solvent removal product thereof. In the present invention, these herbal medicines are administered orally. By this administration, the absorption of the pharmacologically active substance administered by a route different from the oral route into the living body and the arrival at the diseased site can be improved, and the bioavailability of the pharmacologically active substance can be increased. The preferred dosage of the essence of the herbal medicine having a sluice action, which is a distribution improving agent of these pharmacologically active substances of the present invention, is preferably 10 to 20000 g per day for each adult and divided into several times. is there. The administration is preferably performed prior to the administration of the pharmacologically active substance, and the timing is preferably 1 hour to 30 minutes before the administration of the pharmacologically active substance. Also particularly noteworthy is to improve the absorption of pharmacologically active substances from the skin with less blood influence and the arrival at the disease site. That is, this is because, in the skin where the metabolism, absorption and excretion by blood cannot be expected greatly, the tsuyu action referred to Kampo takes on this action instead. The distribution improving agent for pharmacologically active substances of the present invention includes excipients, binders, coating agents, lubricants, sugar coatings, disintegrants, extenders, flavoring agents, emulsifying / solubilizing / dispersing agents, stabilizing agents. It is also possible to formulate and use together with optional components such as an agent, a pH adjuster and an isotonic agent.
（２）本発明で使用される薬理活性物質本発明で使用されうる薬理活性物質としては、上記津液作用を有する生薬と異なる投与経路で投与される、生理活性を有する物質であれば特段の限定なく使用することが可能であり、例えば、医薬品であれば、注射、坐剤、皮膚外用等の経路で投与される、催眠・鎮静薬、解熱・鎮痛薬、興奮・覚醒薬、鎮暈薬、精神神経用薬、鎮ケイ薬、抗ヒスタミン剤、アレルギー疾患用薬、循環器用薬、呼吸器用薬、抗潰瘍剤、下剤、ホルモン剤、抗真菌剤、ビタミン、抗生物質、抗炎症剤、抗悪性腫瘍剤等が例示でき、化粧料などでは美白成分、シワ改善成分、美肌成分、育毛成分、血行促進成分、くすみ改善成分、化粧崩れ防止成分等が例示できる。これらは、上記本発明の薬理活性物質の分布改善が存在していると、皮膚からの取込や、疾患部位への到達が改善され、その生体利用率が向上する。これら薬理活性を有する物質は、通常の用例に従って投与すればよい。 (2) Pharmacologically active substance used in the present invention The pharmacologically active substance that can be used in the present invention is not particularly limited as long as it is a substance having a physiological activity that is administered by a different administration route from the above-mentioned crude drug having a tsunami action. For example, if it is a pharmaceutical, it is administered by routes such as injection, suppository, topical skin, hypnotic / sedative, antipyretic / analgesic, stimulant / stimulant, antipruritic, mental Nervous drugs, silicicidal drugs, antihistamines, allergic diseases drugs, cardiovascular drugs, respiratory drugs, anti-ulcer drugs, laxatives, hormone drugs, antifungal drugs, vitamins, antibiotics, anti-inflammatory drugs, anti-neoplastic agents, etc. Examples of cosmetics include whitening ingredients, wrinkle-improving ingredients, skin-beautifying ingredients, hair-restoring ingredients, blood circulation promoting ingredients, dullness-improving ingredients, and cosmetic break-up preventing ingredients. When the distribution improvement of the pharmacologically active substance of the present invention is present, the uptake from the skin and the arrival at the diseased site are improved, and the bioavailability is improved. These substances having pharmacological activity may be administered according to usual examples.
本発明によれば、薬理作用を有する物質の体内分布や生体利用度を改善する手段を提供することができる。 ADVANTAGE OF THE INVENTION According to this invention, the means to improve the biodistribution and bioavailability of the substance which has a pharmacological action can be provided.
以下に実施例を挙げて本発明について更に詳細に説明を加えるが、本発明がこれら実施例にのみ限定を受けないことは言うまでもない。 Hereinafter, the present invention will be described in more detail with reference to examples, but it is needless to say that the present invention is not limited to these examples.
＜実施例１＞
津液作用を有する次の生薬のそれぞれ１Ｋｇに水５ｌを加え、３時間煮沸した。これを濾過して不溶物を除去し、凍結乾燥し本発明の薬理活性物質の分布改善剤を得た。このものを１００ｍｇ／Ｋｇのドーズで０．１ｍｌの生理食塩水に溶解させて、予め除毛したＩＣＲマウス（１群３匹）に経口投与し、その投与後３０分に除毛部位に１ｍｇのミノキシジルをエタノール１００μｌに溶かして経皮投与した。対照群は本発明の薬理活性物質の分布改善剤の生理食塩水溶液の替わりに０．１ｍｌの生理食塩水を投与した。投与後２週間に、毛の生え具合を＋＋：対照群に比し非常に多い、＋：対照群に比し多い、±：対照群に比しやや多い、−：対照群と同じかそれ以下の基準で観察・判定した。結果を表１に示す。これより、本発明の薬理活性物質の分布改善剤により、育毛料であるミノキシジルの育毛効果が増強していることがわかる。
<Example 1>
5 l of water was added to 1 kg of each of the following herbal medicines having a tsunami effect and boiled for 3 hours. This was filtered to remove insolubles and freeze-dried to obtain the distribution improving agent for pharmacologically active substances of the present invention. This was dissolved in 0.1 ml of physiological saline at a dose of 100 mg / Kg, and orally administered to ICR mice (three mice per group) previously depigmented. Minoxidil was dissolved in 100 μl of ethanol and administered transdermally. In the control group, 0.1 ml of physiological saline was administered instead of the physiological saline solution of the pharmacologically active substance distribution improving agent of the present invention. Two weeks after administration, hair growth is ++: much higher than the control group, +: more compared to the control group, ±: slightly higher than the control group, −: less than or equal to the control group Observed and judged according to the criteria. The results are shown in Table 1. From this, it can be seen that the hair growth effect of minoxidil, which is a hair restorer, is enhanced by the pharmacologically active substance distribution improving agent of the present invention.
＜実施例２＞
津液作用を有する次の生薬のそれぞれ１Ｋｇに水５ｌを加え、３時間煮沸した。これを濾過して不溶物を除去し、凍結乾燥し本発明の薬理活性物質の分布改善剤を得た。このものを１００ｍｇ／Ｋｇのドーズで０．１ｍｌの生理食塩水に溶解させて、予め１０日前にエーリッヒの腹水癌を１０4個を０．１ｍｌの生理食塩水に分散し、背部皮内に投与し、癌を移植しておいたＩＣＲマウス（１群３匹）に経口投与し、その投与後３０分にアドリアマイシン１０ｍｇ／Ｋｇを静脈内投与した。対照群は本発明の薬理活性物質の分布改善剤の生理食塩水溶液の替わりに０．１ｍｌの生理食塩水を経口投与した。投与後２週間に、癌の大きさを計測し、＋＋：対照群に比して非常に小さい、＋：対照群に比し小さい、±：対照群に比しやや小さい、対照群と同じかそれ以上の基準で判定した。結果を表２に示す。これより、本発明の薬理活性物質の分布改善剤により、抗癌剤であるアドリアマイシンの抗癌効果が増強していることがわかる。
<Example 2>
5 l of water was added to 1 kg of each of the following herbal medicines having a tsunami effect and boiled for 3 hours. This was filtered to remove insolubles and freeze-dried to obtain the distribution improving agent for pharmacologically active substances of the present invention. This was dissolved in 0.1 ml of physiological saline at a dose of 100 mg / kg, and 10 4 Erich's ascites tumors were dispersed in 0.1 ml of physiological saline 10 days in advance and administered into the back skin. Then, it was orally administered to ICR mice (3 mice per group) in which cancer had been transplanted, and adriamycin 10 mg / Kg was intravenously administered 30 minutes after the administration. In the control group, 0.1 ml of physiological saline was orally administered instead of the physiological saline solution of the pharmacologically active substance distribution improving agent of the present invention. Two weeks after administration, the size of the cancer was measured, ++: very small compared to the control group, +: small compared to the control group, ±: slightly smaller than the control group, whether the same as the control group Judgment was made on the basis of more criteria. The results are shown in Table 2. This shows that the anticancer effect of adriamycin, which is an anticancer agent, is enhanced by the pharmacologically active substance distribution improving agent of the present invention.
＜実施例３＞
ウィスター系雄性ラットのフットパッドにカラゲニン浮腫（１群３匹）を作成し、上記薬理活性物質の分布改善剤を１００ｍｇ／Ｋｇのドーズで０．１ｍｌの生理食塩水に溶解させ、経口投与した。対照群は生理食塩水のみを投与した。このカラゲニン浮腫ラットに、ワセリン中にインドメタシンを１重量％練り込んだ軟膏を塗布し、その２４時間後に浮腫の大きさを次の基準で判定した。＋＋：対照群に比べて著しく浮腫が小さい、＋：対照群に比べて浮腫が明らかに小さい、±：対照群に比しやや浮腫が小さい、−：対照群と浮腫の大きさが同じか乃至は大きい、の基準で判定した。結果を表３に示す。この表より、本発明の薬理活性物質の分布改善剤の投与により、インドメタシンの抗炎症作用が増強していることがわかる。
<Example 3>
Carrageenan edema (3 mice per group) was created on the foot pad of Wistar male rats, and the above-mentioned pharmacologically active substance distribution improving agent was dissolved in 0.1 ml of physiological saline at a dose of 100 mg / Kg and orally administered. The control group received saline alone. The carrageenin edema rat was applied with an ointment containing 1% by weight of indomethacin in petrolatum, and 24 hours later, the size of the edema was determined according to the following criteria. ++: Significantly smaller edema compared to the control group, +: Obviously smaller edema than the control group, ±: Slightly smaller edema than the control group,-: The size of the edema is the same as the control group Was judged on the basis of large. The results are shown in Table 3. This table shows that the anti-inflammatory action of indomethacin is enhanced by the administration of the pharmacologically active substance distribution improving agent of the present invention.
＜実施例４＞
色黒に悩む２１〜３４歳の２０人の女性パネラーを対象に、下記の化粧水の色黒改善について使用テストを行った。パネラーは無作為に２群に分け、１群には化粧水使用３０分前に猪苓の水抽出物の凍結乾燥品０．５ｇを服用してもらい、他の１群は化粧水のみを使用してもらった。化粧水を３カ月使用した後、色黒の改善を、＋＋：著しく改善した、＋：明確に改善した、±：やや改善した、−：改善しないか改悪した、の基準でアンケートに答えてもらった。結果を出現例数として、表４に示す。これより、本発明の薬理活性物質の分布改善剤である、猪苓のエッセンスを服用した群の方が優れた色黒改善効果を示していることがわかる。
<Example 4>
Using 20 female panelists aged 21 to 34 who suffer from darkness, a use test was conducted to improve the darkness of the following lotion. The panelists were randomly divided into two groups, one group taking 0.5g of lyophilized water extract of persimmon 30 minutes before using lotion, and the other group using lotion only I was asked to. After using the skin lotion for 3 months, the black-and-white improvement was answered on the basis of ++: markedly improved, +: clearly improved, ±: slightly improved,-: not improved or corrupted. It was. The results are shown in Table 4 as the number of appearance examples. From this, it can be seen that the group taking the essence of wrinkles, which is the distribution improving agent for the pharmacologically active substance of the present invention, shows an excellent color blackness improving effect.
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006287967A JP2007008965A (en) | 2006-10-23 | 2006-10-23 | Hair growing agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006287967A JP2007008965A (en) | 2006-10-23 | 2006-10-23 | Hair growing agent |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP10044361A Division JPH11228435A (en) | 1998-02-10 | 1998-02-10 | Pharmacologically active substance distribution improver |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2007008965A true JP2007008965A (en) | 2007-01-18 |
Family
ID=37747883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006287967A Pending JP2007008965A (en) | 2006-10-23 | 2006-10-23 | Hair growing agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2007008965A (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100878596B1 (en) | 2007-09-13 | 2009-01-15 | 우석대학교 산학협력단 | A composition for anti-dandruff and itch-removal hair cosmetics and a method for preparing the same |
| JP2010215579A (en) * | 2009-03-18 | 2010-09-30 | Michiharu Sasaki | Hair nourishing liquid |
| CN102895401A (en) * | 2012-10-31 | 2013-01-30 | 王丽娟 | Germinal traditional Chinese medicine and preparation method thereof |
| JP2013112684A (en) * | 2011-11-29 | 2013-06-10 | Amorepacific Corp | Composition for prevention of depilation or promotion of hair growth |
| WO2014189159A1 (en) * | 2013-05-22 | 2014-11-27 | Kim Kwang Soo | Pharbitis nil (l.) choisy extract-containing composition for preventing hair loss and promoting hair growth |
| CN105213259A (en) * | 2015-10-26 | 2016-01-06 | 山东师范大学 | One gives birth to eyebrow compositions and the raw eyebrow of natural wash-free is excellent and preparation method |
| CN108837121A (en) * | 2018-09-02 | 2018-11-20 | 刘德平 | A kind of Chinese medicine composition and preparation method thereof for treating high lithemia |
| CN110664964A (en) * | 2019-10-31 | 2020-01-10 | 武汉泰安康生物科技有限公司 | Medicine for preventing and treating urinary calculus and preparation method thereof |
| CN113679650A (en) * | 2021-09-18 | 2021-11-23 | 韶关市曲江美达多食品加工有限公司 | Asparagus cochinchinensis shampoo with effects of hairdressing and hair care |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61165312A (en) * | 1985-01-14 | 1986-07-26 | Takeo Kinji | Hair tonic cosmetic |
| JPS6438010A (en) * | 1987-07-31 | 1989-02-08 | Pola Chem Ind Inc | Promoter for hair restoration and hair growth |
| JPH02502818A (en) * | 1987-03-30 | 1990-09-06 | ジ・アップジョン・カンパニー | Combination of minoxidil and anti-inflammatory agents to treat hereditary alopecia |
| JPH03188013A (en) * | 1989-12-15 | 1991-08-16 | Shiseido Co Ltd | Testosterone-5alpha-reductase inhibitor |
| JPH0436221A (en) * | 1990-05-29 | 1992-02-06 | Sunstar Inc | Hair tonic |
| JPH0570360A (en) * | 1991-09-10 | 1993-03-23 | Lion Corp | Androgenic hormone-resistant agent |
| JPH0753338A (en) * | 1993-08-10 | 1995-02-28 | Taisho Pharmaceut Co Ltd | Hair tonic |
| JPH0820522A (en) * | 1994-07-07 | 1996-01-23 | Pola Chem Ind Inc | Keratinizing anzyme activity promoter and cosmetic containing the same |
| JPH0873324A (en) * | 1994-09-06 | 1996-03-19 | Kao Corp | Hair-tonic and hair-growing agent |
| JPH10218737A (en) * | 1997-02-10 | 1998-08-18 | Taisho Pharmaceut Co Ltd | Hair grower |
-
2006
- 2006-10-23 JP JP2006287967A patent/JP2007008965A/en active Pending
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61165312A (en) * | 1985-01-14 | 1986-07-26 | Takeo Kinji | Hair tonic cosmetic |
| JPH02502818A (en) * | 1987-03-30 | 1990-09-06 | ジ・アップジョン・カンパニー | Combination of minoxidil and anti-inflammatory agents to treat hereditary alopecia |
| JPS6438010A (en) * | 1987-07-31 | 1989-02-08 | Pola Chem Ind Inc | Promoter for hair restoration and hair growth |
| JPH03188013A (en) * | 1989-12-15 | 1991-08-16 | Shiseido Co Ltd | Testosterone-5alpha-reductase inhibitor |
| JPH0436221A (en) * | 1990-05-29 | 1992-02-06 | Sunstar Inc | Hair tonic |
| JPH0570360A (en) * | 1991-09-10 | 1993-03-23 | Lion Corp | Androgenic hormone-resistant agent |
| JPH0753338A (en) * | 1993-08-10 | 1995-02-28 | Taisho Pharmaceut Co Ltd | Hair tonic |
| JPH0820522A (en) * | 1994-07-07 | 1996-01-23 | Pola Chem Ind Inc | Keratinizing anzyme activity promoter and cosmetic containing the same |
| JPH0873324A (en) * | 1994-09-06 | 1996-03-19 | Kao Corp | Hair-tonic and hair-growing agent |
| JPH10218737A (en) * | 1997-02-10 | 1998-08-18 | Taisho Pharmaceut Co Ltd | Hair grower |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100878596B1 (en) | 2007-09-13 | 2009-01-15 | 우석대학교 산학협력단 | A composition for anti-dandruff and itch-removal hair cosmetics and a method for preparing the same |
| JP2010215579A (en) * | 2009-03-18 | 2010-09-30 | Michiharu Sasaki | Hair nourishing liquid |
| JP2013112684A (en) * | 2011-11-29 | 2013-06-10 | Amorepacific Corp | Composition for prevention of depilation or promotion of hair growth |
| CN102895401A (en) * | 2012-10-31 | 2013-01-30 | 王丽娟 | Germinal traditional Chinese medicine and preparation method thereof |
| WO2014189159A1 (en) * | 2013-05-22 | 2014-11-27 | Kim Kwang Soo | Pharbitis nil (l.) choisy extract-containing composition for preventing hair loss and promoting hair growth |
| KR101733552B1 (en) | 2013-05-22 | 2017-05-12 | 김성욱 | Pharbitis nil (l.) choisy extract-containing composition for preventing hair loss and promoting hair growth |
| CN105213259A (en) * | 2015-10-26 | 2016-01-06 | 山东师范大学 | One gives birth to eyebrow compositions and the raw eyebrow of natural wash-free is excellent and preparation method |
| CN108837121A (en) * | 2018-09-02 | 2018-11-20 | 刘德平 | A kind of Chinese medicine composition and preparation method thereof for treating high lithemia |
| CN110664964A (en) * | 2019-10-31 | 2020-01-10 | 武汉泰安康生物科技有限公司 | Medicine for preventing and treating urinary calculus and preparation method thereof |
| CN113679650A (en) * | 2021-09-18 | 2021-11-23 | 韶关市曲江美达多食品加工有限公司 | Asparagus cochinchinensis shampoo with effects of hairdressing and hair care |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Seeff et al. | Complementary and alternative medicine in chronic liver disease | |
| JP2007008965A (en) | Hair growing agent | |
| CN103989668A (en) | Application of fructus forsythiae aglycone in preparing medicament for preventing or treating liver injury or liver failure | |
| Musthaba et al. | Patented herbal formulations and their therapeutic applications | |
| JP2007016053A (en) | Antineoplastic agent | |
| KR100688252B1 (en) | Composition for improving male sexual function | |
| Katana | Effectiveness of pomegranate Punica Granatum L. fruit extract on the sexual function in rats | |
| CN104491310B (en) | Anti-Fatigue Composition and its preparation method and application | |
| CN107213197A (en) | A kind of Chinese medicine composition and its application in prevention or treatment hypertension drug is prepared | |
| CN113456778A (en) | Composition for improving energy and preparation method thereof | |
| CN102526387B (en) | Medicinal composition for treating early-stage diabetic foot and preparation method thereof | |
| CN104436022A (en) | Hemsleya-macrosperma-containing traditional Chinese medicine composition for treating diabetes mellitus | |
| CN101732657A (en) | Medicine composition | |
| CN100486621C (en) | Chinese medicinal composition for treating hemilateral headache and its preparation method | |
| Bhardwaj et al. | Development of cucurbocitrin based nutraceutical formulation: A potential adjuvant herbal therapy in the management of hypertension | |
| CN103920023A (en) | Traditional Chinese medicine for treating hypertension | |
| CN104352974A (en) | Ciliatenerve knotweed root-containing traditional Chinese medicine composition for treating diabetes | |
| CN108704036A (en) | A kind of Chinese traditional compound medicine and preparation method thereof for treating gout | |
| CN103705868B (en) | One treats hyperthyroid pharmaceutical composition and application thereof | |
| CN105944104A (en) | Pharmaceutical composition for treating digestive tract ulcer | |
| CN102133274A (en) | Chinese medicinal composition | |
| JPH11228435A (en) | Pharmacologically active substance distribution improver | |
| CN100502927C (en) | Medication of three gen-seng and astragalus root and its preparation method | |
| CN104337898A (en) | Traditional Chinese medicine composition containing bunge cherry seeds for treating gout | |
| CN105456316A (en) | Plumeria rubra drop pill and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20061023 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100413 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100817 |